# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ascendis Pharma reported lower-than-expected Q2 2024 sales of $38.76 million, missing the consensus estimate of $92.7 million d...
Jim Cramer discusses Snowflake, Royalty Pharma, Core Scientific and Ally Financial on "Mad Money Lightning Round."
Goldman Sachs analyst Chris Shibutani maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $50...
Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $0.96 per share which missed the analyst consensus estimate of $0.9...
Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target fr...